Deoxyribozyme-nanosponges for improved photothermal therapy by overcoming thermoresistance

Jin, Y.; Liang, Linna; Sun, Xiaojing; Yu, Guangshun; Chen, Shizhu; Shi, Shutang; Liu, Huifang; Li, Zhenhua; Ge, Kun; Liu, Dandan; Yang, Xinjian; Zhang, Jinchao

doi:10.1038/s41427-018-0040-7

Cited by 26 publications

(26 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two 10-23 DNAzyme sequences in the template caused suppression of Egr-1 and survivin in MCF-7 tumor xenografts, increased apoptosis and reduced tumor size (11). Recent studies with DNAzymebased nanosponges, in which long single-stranded DNAzyme sequences targeting heat shock protein 70 (HSP70) synthesized by RCA were assembled with cationic polymer, sensitized MCF-7 cells to heat and, after intravenous administration, localized within tumors via the EPR effect and improved photothermal therapeutic efficiency (71). Future studies with other key molecular targets should determine the wider utility of these clinically relevant complexed approaches.…”

Section: Targeting Angiogenesismentioning

confidence: 99%

Deoxyribozymes as Catalytic Nanotherapeutic Agents

Khachigian

2019

Cancer Research

View full text Add to dashboard Cite

RNA-cleaving deoxyribozymes (DNAzymes) are synthetic single-stranded DNA-based catalytic molecules that can be engineered to bind to and cleave target mRNA at predetermined sites. These have been used as therapeutic agents in a range of preclinical cancer models and have entered clinical trials in Europe, China, and Australia. This review surveys regulatory insights into mechanisms of disease brought about by use of catalytic DNA in vitro and in vivo, including recent uses as nanosensors, nanoflowers, and nanosponges, and the emerging role of adaptive immunity underlying DNAzyme inhibition of cancer growth. DNAzymes represent a promising new class of nucleic acid-based therapeutics in cancer. This article discusses mechanistic and therapeutic insights brought about by DNAzyme use as nanotools and reagents in a range of basic science, experimental therapeutic and clinical applications. Current limitations and future perspectives are also discussed.

show abstract

Section: Targeting Angiogenesismentioning

confidence: 99%

Deoxyribozymes as Catalytic Nanotherapeutic Agents

Khachigian

2019

Cancer Research

View full text Add to dashboard Cite

show abstract

Section: Molecular Engineering Of Nucleic Acid Enzyme–based Nanomatermentioning

confidence: 99%

“…The resultant DNF was capable for cancer cell recognition, multiple gene silencing, and induction of apoptosis. Similarly, by replacing magnesium pyrophosphate with a cationic polymer, the same group further developed a sponge‐like platform for high‐efficiency photothermal therapy (Figure D) . Similarly, Li et al developed a multifunctional DNA nanosorption nanostructure using aptamers and DNAzyme for highly efficient targeted delivery and release of therapeutic mRNA for gene therapy …”

Section: Molecular Engineering Of Nucleic Acid Enzyme–based Nanomatermentioning

confidence: 99%

Molecular Engineering of Functional Nucleic Acid Nanomaterials toward In Vivo Applications

Zhang

Lan

2019

Adv Healthcare Materials

View full text Add to dashboard Cite

equally exciting and perhaps more challenging field of application is toward their in vivo applications, including living animals and human bodies, in diverse areas, [2] such as sensing, drug delivery, medical imaging, and cancer therapy. However, most of these nanomaterials lack selectivity toward targets of interests. Therefore, to employ these nanomaterials for a wider range of in vivo applications, various molecular engineering approaches have been employed to obtained nanomaterials functionalized with biomolecules to enable selective targeting. [3][4][5] Among these biomolecules, functional nucleic acids, or FNAs, have shown the most promise.FNAs are DNA or RNA molecules that can interact with or bind to a specific analyte, resulting in a conformational change and/or a catalytic reaction. [6] As their names suggested, ribozymes and deoxyribozymes (called DNAzyme hereafter) can act as enzymes in the presence of cofactors to catalyze various reactions, including cleavage and ligation of RNA/DNA, and phosphorylation and peroxidation of DNA. On the other hand, riboswitches and DNA aptamers are antibody-like receptors that can bind target molecules with high affinity and selectivity. Furthermore, the binding abilities of riboswitches and aptamers can be combined with the enzymatic function of ribozymes or DNAzymes to form aptazymes so that the binding of targets can inhibit or enhance the catalytic activities. These nucleic acids, including DNAzymes, aptamers, and aptazymes, are collectively known as FNAs to emphasize their functions beyond the traditional genetic storage and transformations roles for DNA and RNA. Unlike DNA and RNA inside biological systems, FNAs are isolated via a combinatorial technique known as in vitro selection, or a process also known as systematic evolution of ligands by exponential enrichment (SELEX). The discovery of new functions of nucleic acids has not only resulted in major advances in the fields of molecular biology and biochemistry, but also revolutionized sensors designs for both in vitro and in vivo applications. [7,8] Over the past decade, numerous FNA-based nanomaterials have been developed. [9][10][11][12] Among these FNA-based nanosystems, the functions of FNAs can be categorized into two types: diagnostic function and therapeutic function. For the diagnostic function, the FNAs serve either as the biorecognition ligands for direct sensing and imaging of the Recent advances in nanotechnology and engineering have generated many nanomaterials with unique physical and chemical properties. Over the past decade, numerous nanomaterials are introduced into many research areas, such as sensors for environmental monitoring, food safety, point-ofcare diagnostics, and as transducers for solar energy transfer. Meanwhile, functional nucleic acids (FNAs), including nucleic acid enzymes, aptamers, and aptazymes, have attracted major attention from the biomedical community due to their unique target recognition and catalytic properties. Benefiting from the recent progress of molecular engine...

show abstract

“…Cancer is one of the most life-threatening diseases in the world, and the development of an efficient therapeutic reagent for cancer therapy is of great importance in cancer research [79][80][81]. In addition to the use of conventional chemotherapeutic drugs for cancer therapy, RCDs have recently been evidentially recognized as a new type of therapeutic agent [82][83][84][85]. Li et al designed a DNAzyme-based walker system [82] that could control the release of the oligonucleotide drug AS1411 for breast cancer treatment ( Figure 8A).…”

Section: In Vivo Cancer Therapymentioning

confidence: 99%

“…The formed DNF exhibits multiple built-in functions, including targeted cancer cell recognition, dual gene silencing, induction of apoptosis, and inhibition of tumor growth, suggesting great promise for enhanced cancer therapy. Using a similar strategy, the same group further developed a DNAzyme-nanosponge therapeutic platform for the highly efficient photothermal treatment of cancer through catalytically restraining the expression of the survival protein [84].…”

Section: In Vivo Cancer Therapymentioning

confidence: 99%

RNA-Cleaving DNAzymes: Old Catalysts with New Tricks for Intracellular and In Vivo Applications

Zhang

2018

Catalysts

View full text Add to dashboard Cite

DNAzymes are catalytically active DNA molecules that are normally isolated through in vitro selection methods, among which RNA-cleaving DNAzymes that catalyze the cleavage of a single RNA linkage embedded within a DNA strand are the most studied group of this DNA enzyme family. Recent advances in DNA nanotechnology and engineering have generated many RNA-cleaving DNAzymes with unique recognition and catalytic properties. Over the past decade, numerous RNA-cleaving, DNAzymes-based functional probes have been introduced into many research areas, such as in vitro diagnostics, intracellular imaging, and in vivo therapeutics. This review focus on the fundamental insight into RNA-Cleaving DNAzymes and technical tricks for their intracellular and in vivo applications, highlighting the recent progress in the clinical trial of RNA-Cleaving DNAzymes with selected examples. The challenges and opportunities for the future translation of RNA-cleaving DNAzymes for biomedicine are also discussed.

show abstract

Deoxyribozyme-nanosponges for improved photothermal therapy by overcoming thermoresistance

Cited by 26 publications

References 36 publications

Deoxyribozymes as Catalytic Nanotherapeutic Agents

Deoxyribozymes as Catalytic Nanotherapeutic Agents

Molecular Engineering of Functional Nucleic Acid Nanomaterials toward In Vivo Applications

RNA-Cleaving DNAzymes: Old Catalysts with New Tricks for Intracellular and In Vivo Applications

Contact Info

Product

Resources

About